DrugPatentWatch Database Preview

Rucaparib camsylate - Generic Drug Details

What are the generic sources for rucaparib camsylate and what is the scope of rucaparib camsylate patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and thirty-six patent family members in fifty-two countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate

International Patents:	236
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	11
Clinical Trials:	4
Patent Applications:	2
DailyMed Link:	rucaparib camsylate at DailyMed

Pharmacology for rucaparib camsylate

Drug Class	Poly(ADP-Ribose) Polymerase Inhibitor
Mechanism of Action	Poly(ADP-Ribose) Polymerase Inhibitors

US Patents and Regulatory Information for rucaparib camsylate

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		➤ Sign Up
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

International Patents for rucaparib camsylate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Japan	2016216507	➤ Sign Up
Russian Federation	2006121459	➤ Sign Up
China	1342161	➤ Sign Up
Norway	335959	➤ Sign Up
Croatia	P20050895	➤ Sign Up
European Patent Office	1649017	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for rucaparib camsylate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
15/016	Ireland	➤ Sign Up	PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
0150012 00136	Estonia	➤ Sign Up	PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
680	Luxembourg	➤ Sign Up	PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
90019-4	Sweden	➤ Sign Up	PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
/2015	Austria	➤ Sign Up	PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
2015016	Lithuania	➤ Sign Up	PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description